Gene-mutation pathway discovery paves way for targeted blood cancers therapies

October 3, 2024

  Approximately 30% of individuals with myeloid malignancy diseases have a mutation in a certain gene called tet methylcytosine dioxygenase 2 (TET2). This gene is responsible for providing instructions on creating certain proteins and is known to have a tumor-suppressive function. A study published October 2 in Nature is the first to explain the pathway […]





University awarded $12 million to further develop opioid use disorder drug

September 30, 2024

Charles P. France, PhD, to lead methocinnamox drug development program The University of Texas Health Science Center at San Antonio (UT Health San Antonio) was awarded a $12 million cooperative agreement (U01) from the National Institutes of Health’s National Institute on Drug Abuse to further develop methocinnamox (MCAM) as a treatment for opioid use disorder. […]



UT Health San Antonio awarded $12.6 million program grant for cancer research

September 19, 2024

The University of Texas Health Science Center at San Antonio  (UT Health San Antonio) was recently awarded a $12.6 million program project grant (P01) from the National Institutes of Health’s National Cancer Institute to expand collaborative efforts to explore the biological mechanisms of BRCA1, BRCA2 and related tumor suppressors and to shed light on potential […]


UT Health San Antonio finds higher levels of leptin indicate brain protection against late-life dementia

September 18, 2024

Weight-maintaining hormone key to brain-signal transmission New research is more closely linking obesity to dementia. Higher levels of leptin, a hormone that helps maintain normal body weight, is associated with better signal-transmitting brain white matter in middle-aged adults, according to a study by The University of Texas Health Science Center at San Antonio (UT Health […]